Bronchial Spasm Market Size, Share, Industry, Forecast and outlook (2024-2031)

Bronchial Spasm Market is segmented By Treatment Type (Bronchodilators, Steroids, Leukotriene Antagonists, Others), By Route of Administration (Oral, Inhalational, Others), By Patient Type (Pediatrics, Adults, Geriatrics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Report Overview

The Global Bronchial Spasm Market reached US$ 424.36 million in 2023 and is expected to reach US$ 650.05 million by 2031, growing at a CAGR of 5.6% during the forecast period 2024-2031. 

Bronchial spasm, also known as bronchospasm, is a sudden contraction of bronchial smooth muscles causing the narrowing of bronchi. Allergens usually trigger a cascade of inflammatory or excessive muscle contraction events, that result in bronchospasm. The most common symptoms are wheezing and cough, which range from mild to severe. The incidence of bronchospasm is higher in patients with conditions such as asthma, COPD, emphysema, bronchitis, and other inflammatory conditions related to the airway tract.

Market Scope

For more details on this report - Request for Sample

Market Dynamics: Drivers

Rising prevalence of bronchospasm with associated comorbidities

Bronchial spasms can occur in anyone but are more prevalent among patients with associated co-morbidities such as asthma and COPD. Bronchospasm is one of the major symptoms in patients with these conditions, and as their prevalence grows, the patient population experiencing bronchospasm concurrently rises, creating a demand for therapeutics.

For instance, as per the Global Burden of Asthma study published in the Journal of Asthma and Allergy in October 2023, the prevalence of asthma in Asia was 3.44%, 3.67% in Africa, 4.90% in South America, 5.69% in Europe, 8.29% in North America and 8.33% in Oceania. Among the global asthmatic population globally, 26.70% had severe asthma, 30.99% had eosinophilic asthma, 48.95% had allergic rhinitis, and 7.0% to 25.40% had nasal polyps.

Among this prevalent population, the risk of hypersensitivity reactions such as bronchospasm highly increases if they take Non-steroidal anti-inflammatory drugs, or undergo surgery under general anesthesia. As per the New Zealand Medicine and Medical Device Safety Authority, 8 to 20% of asthmatics experience bronchospasm within 20 minutes to 3 hours after the ingestion of NSAIDs. This is termed Aspirin-induced asthma and can be fatal in some patient populations.

As the population ages, the incidence of NSAID administration may increase to alleviate age-related painful conditions, which may exacerbate bronchospasm. Hence the rising prevalence of asthma and COPD may contribute to increased incidence of bronchospasm, propelling the treatment market growth positively.

Restraints

The market for bronchial spasms is restrained by several factors such as side effects associated with the use of corticosteroids and bronchodilators, higher chances of misdiagnosis which may lead to improper treatment approaches, as well as supply chain discrepancies and drug shortages etc.

Market Segment Analysis

The global bronchial spasm market is segmented based on treatment type, route of administration patient type, distribution channel, and region.

Bronchodilators in the treatment type segment accounted for approximately 56./4% of the global bronchial spasm market share

Bronchodilators are a group of medications, that act on bronchial smooth muscles and relax them causing a dilatory effect and clearing the obstruction in the airway passage. There are several classes of bronchodilators, which majorly include beta-2 receptor agonists, anticholinergics, and xanthine derivatives. Beta-2 receptor agonists include albuterol (salbutamol) and salmeterol, these are termed short-acting bronchodilators that provide immediate relief to the patient. The other class of drugs- anticholinergics, including ipratropium and triotropium, are long-acting bronchodilators that provide long-term relief to patients. 

These bronchodilators especially beta-2 receptor agonists are widely used during the acute attacks of bronchospasm and are recommended, for first-line use. As per the National Centre for Biotechnology Information article published in January 2024, Albuterol is the first line agent approved in the U.S. by the FDA to treat and prevent acute or severe bronchospasm. Post approval, many companies have developed and launched their products for clinical use all across the globe. At present several branded versions have lost their patent exclusivity, and there is a surge of generic bronchodilators in the market.

Market Geographical Share

North America dominates the global bronchial spasm market with a share of 43..5% in 2023, and growing at a CAGR of XX% in the forecast period.

North America dominates the global bronchial spasm market due to its advanced healthcare infrastructure and facilities, easy accessibility to a variety of treatments, availability of branded drugs offered by global pharmaceutical industry leaders, and increasing prevalence, etc.

For instance, according to the Asthma and Allergy Foundation of America's recent updates in April 2024, Over 27 million people in the U.S. have asthma, which equals 1 in 12 people. Moreover, it is the leading chronic disease in children accounting for approximately 4.5 million cases. As per the Center for Disease Control and Prevention, in 2022, approximately 8.7% of U.S. adults above 18 years of age are living with Asthma, and 6.2% of children below 18 years of age are living with asthma. Among these asthmatic patients, the incidence of bronchospasm is also higher.

Hence, considering these factors, along with the epidemiological data and sales figures by market leaders, North America is designated as a dominant region in the global market.

Market Segmentation

By Treatment Type

• Bronchodilators
  • Beta 2 Agonists
    • Albuterol
    • Salmeterol
    • Others
  • Anticholinergics
    • Ipratropium Bromide
    • Tiotropium Bromide
    • Others
  • Xanthine Derivatives
• Steroids
• Leukotriene Antagonists
• Others

By Route of Administration

• Oral
• Inhalational
• Others

By Patient Type

• Pediatrics
• Adults
• Geriatrics

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Market Competitive Landscape

The major players in the bronchial spasm market include Teva Pharmaceuticals USA, Inc., Cipla., GSK plc., Nephron Pharmaceuticals Corporation., Boehringer Ingelheim International GmbH., Sandoz AG, AstraZeneca., Organon group of companies., Viatris Inc. and Lupin Pharmaceuticals, Inc. among others.

Why Purchase the Report?

• To visualize the global bronchial spasm market segmentation based on treatment type, route of administration, patient type, distribution channel, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of bronchial spasm market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global bronchial spasm market report would provide approximately 70 tables, 63 figures, and 212 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies